Leerink Swann restated their market perform rating on shares of AbbVie Inc. (NYSE:ABBV) in a research note issued to investors on Tuesday.

Other analysts have also recently issued reports about the stock. BMO Capital Markets reiterated a market perform rating and issued a $66.00 target price on shares of AbbVie in a research note on Wednesday, May 17th. Piper Jaffray Companies reiterated a buy rating and issued a $85.00 target price on shares of AbbVie in a research note on Thursday, August 3rd. Evercore ISI assumed coverage on shares of AbbVie in a research note on Wednesday, August 16th. They issued an outperform rating and a $95.00 target price for the company. Vetr cut shares of AbbVie from a buy rating to a hold rating and set a $72.72 target price for the company. in a research note on Wednesday, June 14th. Finally, BidaskClub cut shares of AbbVie from a strong-buy rating to a buy rating in a research note on Friday, July 28th. Seven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. AbbVie currently has an average rating of Buy and an average target price of $82.38.

AbbVie (NYSE ABBV) opened at 87.37 on Tuesday. The firm has a market capitalization of $139.28 billion, a price-to-earnings ratio of 21.49 and a beta of 1.48. The firm’s 50-day moving average is $74.86 and its 200 day moving average is $69.44. AbbVie has a 12 month low of $55.06 and a 12 month high of $89.69.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 28th. The company reported $1.42 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.40 by $0.02. The firm had revenue of $6.94 billion during the quarter, compared to analysts’ expectations of $6.93 billion. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The company’s revenue was up 7.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.26 earnings per share. Equities analysts predict that AbbVie will post $5.52 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/16/abbvie-inc-abbv-receives-market-perform-rating-from-leerink-swann.html.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be paid a dividend of $0.64 per share. This represents a $2.56 annualized dividend and a yield of 2.93%. The ex-dividend date of this dividend is Thursday, October 12th. AbbVie’s payout ratio is currently 62.90%.

In related news, insider Henry O. Gosebruch sold 18,000 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $70.09, for a total transaction of $1,261,620.00. Following the completion of the transaction, the insider now directly owns 96,074 shares in the company, valued at approximately $6,733,826.66. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of the company’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $85.02, for a total transaction of $705,666.00. Following the transaction, the senior vice president now owns 93,099 shares of the company’s stock, valued at $7,915,276.98. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 373,191 shares of company stock valued at $26,598,305. Corporate insiders own 0.23% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Capital Research Global Investors raised its stake in AbbVie by 1.2% during the 2nd quarter. Capital Research Global Investors now owns 178,274,835 shares of the company’s stock valued at $12,926,708,000 after purchasing an additional 2,130,919 shares during the last quarter. Vanguard Group Inc. raised its stake in AbbVie by 3.3% during the 2nd quarter. Vanguard Group Inc. now owns 115,920,673 shares of the company’s stock valued at $8,405,409,000 after purchasing an additional 3,706,941 shares during the last quarter. BlackRock Inc. raised its stake in AbbVie by 2.0% during the 2nd quarter. BlackRock Inc. now owns 94,074,962 shares of the company’s stock valued at $6,821,375,000 after purchasing an additional 1,864,418 shares during the last quarter. State Street Corp raised its stake in AbbVie by 2.4% during the 1st quarter. State Street Corp now owns 72,969,530 shares of the company’s stock valued at $4,754,696,000 after purchasing an additional 1,696,042 shares during the last quarter. Finally, Orbis Allan Gray Ltd raised its stake in AbbVie by 35.7% during the 2nd quarter. Orbis Allan Gray Ltd now owns 12,704,919 shares of the company’s stock valued at $921,233,000 after purchasing an additional 3,340,038 shares during the last quarter. Hedge funds and other institutional investors own 68.29% of the company’s stock.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.